全文获取类型
收费全文 | 4117篇 |
免费 | 350篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 126篇 |
妇产科学 | 108篇 |
基础医学 | 421篇 |
口腔科学 | 144篇 |
临床医学 | 414篇 |
内科学 | 725篇 |
皮肤病学 | 94篇 |
神经病学 | 300篇 |
特种医学 | 116篇 |
外科学 | 629篇 |
综合类 | 155篇 |
一般理论 | 2篇 |
预防医学 | 567篇 |
眼科学 | 68篇 |
药学 | 283篇 |
中国医学 | 2篇 |
肿瘤学 | 273篇 |
出版年
2023年 | 49篇 |
2022年 | 80篇 |
2021年 | 135篇 |
2020年 | 90篇 |
2019年 | 95篇 |
2018年 | 131篇 |
2017年 | 108篇 |
2016年 | 95篇 |
2015年 | 98篇 |
2014年 | 136篇 |
2013年 | 169篇 |
2012年 | 241篇 |
2011年 | 248篇 |
2010年 | 129篇 |
2009年 | 126篇 |
2008年 | 187篇 |
2007年 | 178篇 |
2006年 | 162篇 |
2005年 | 153篇 |
2004年 | 130篇 |
2003年 | 137篇 |
2002年 | 137篇 |
2001年 | 99篇 |
2000年 | 114篇 |
1999年 | 94篇 |
1998年 | 33篇 |
1997年 | 35篇 |
1996年 | 25篇 |
1995年 | 30篇 |
1992年 | 64篇 |
1991年 | 63篇 |
1990年 | 55篇 |
1989年 | 72篇 |
1988年 | 40篇 |
1987年 | 52篇 |
1986年 | 47篇 |
1985年 | 60篇 |
1984年 | 42篇 |
1983年 | 43篇 |
1981年 | 19篇 |
1979年 | 28篇 |
1978年 | 22篇 |
1976年 | 27篇 |
1975年 | 18篇 |
1974年 | 30篇 |
1972年 | 22篇 |
1971年 | 26篇 |
1970年 | 20篇 |
1967年 | 18篇 |
1966年 | 20篇 |
排序方式: 共有4469条查询结果,搜索用时 17 毫秒
111.
Heidemarie K. Laurent Marissa Sbrilli Danyelle Dawson Megan Finnegan Dawn Ramdas‐Neal 《Developmental psychobiology》2021,63(1):88-97
Scientific understanding of mother–infant HPA axis attunement has been limited by discrepant methods for assessing attunement that often conflate different levels of association. We sought to refine the conceptualization of attunement by investigating whether mother–infant cortisol attunement exists as coupling of response trajectories within an acute stress episode, separate from shared developmental patterns and/or overall dyadic similarity in cortisol levels, and whether the degree of attunement depends on within‐ or between‐dyad differences in maternal risk and protective factors. We examined these questions using a longitudinal study with mother/infant salivary cortisol during dyadic stressors at 6, 12, and 18 months postnatal. A three‐level hierarchical linear model showed that sample‐wide associations between mother and infant cortisol were not significant at any level, suggesting normative lack of attunement; however, there was significant variability in degree of attunement across dyads. Concurrent levels of family resources and social support satisfaction predicted lower mother–infant cortisol attunement within the session, and overall (mean) parenting stress predicted the opposite. Follow‐up analyses showed this was typically due to an increase in infants’ (but not their mothers’) within‐session cortisol response slopes with increasing support and decreasing stress. Implications for the role of mother–infant cortisol attunement in intergenerational stress transmission are discussed. 相似文献
112.
113.
Todd A. Astorino Matthew M. Schubert Elyse Palumbo Douglas Stirling David W. McMillan Christina Cooper Jackie Godinez Donovan Martinez Rachael Gallant 《European journal of applied physiology》2013,113(9):2361-2369
Purpose
This study aimed to compare changes in maximal oxygen uptake (VO2max) in response to two regimens of chronic interval training.Methods
Twenty healthy sedentary women (mean ± SD age and VO2max = 23.0 ± 5.7 years and 30.1 ± 4.4 mL kg?1 min?1, respectively) were randomized to complete 12 weeks of one of two interval training regimes, while an additional seven women served as controls. Training was performed 3 days week?1 on a cycle ergometer and consisted of 6–10 bouts of 1 min duration at lower (60–80 % W max = LO, n = 10) or more intense (80–90 % W max = HI, n = 10) workloads separated by a brief recovery. Every 3 weeks, measures of VO2max and W max were repeated to assign new training intensities. Changes in blood pressure and body composition were also examined.Results
Data revealed significant (p < 0.001) improvements in VO2max in LO (22.3 ± 6.9 %) and HI (21.9 ± 11.6 %) that were similar (p > 0.05) between groups. Approximately 60 % of the increase in VO2max in HI was observed in the initial 3 weeks, compared to only 20 % in LO. No change (p > 0.05) in body weight or body composition was revealed in response to training. Results demonstrate that a relatively prolonged regimen of moderate or more intense interval training induces similar improvements in cardiorespiratory fitness, although HI induced greater increases in VO2max early on in training than LO. Completion of more intense interval training may be an effective means to expedite increases in VO2max soon after initiation of exercise training. 相似文献114.
Young athletes' awareness and monitoring of anti‐doping in daily life: Does motivation matter?
下载免费PDF全文
![点击此处可从《Scandinavian journal of medicine & science in sports》网站下载免费的PDF全文](/ch/ext_images/free.gif)
D. K. C. Chan R. J. Donovan V. Lentillon‐Kaestner S. J. Hardcastle J. A. Dimmock D. A. Keatley M. S. Hagger 《Scandinavian journal of medicine & science in sports》2015,25(6):e655-e663
This study was a preliminarily investigation into the prevention of unintentional doping on the basis of self‐determination theory (SDT). Specifically, we examined the relationship between athletes' motives for doping avoidance and their behavior when offered an unfamiliar food product. Participants were young Australian athletes (n = 410) that were offered a free lollipop prior to completing a questionnaire. It was noted whether participants refused to take or eat the lollipop and whether they read the ingredients of the lollipop. The questionnaire assessed autonomous and controlled forms of motivation, amotivation, doping intentions, and adherence regarding doping avoidance behaviors. The results showed that young athletes who adopted controlled reasons to avoid doping in sport (e.g., not getting caught) tended to report higher adherence to behaviors related to avoiding and monitoring banned substances, whereas those who adopted autonomous reasons (e.g., anti‐doping being consistent with life goals) appeared to be more willing to read the ingredients of the provided food. The significant interaction effect between autonomous and controlled motivation indicated that autonomous motivation was more predictive to doping intention for athletes with low controlled motivation. It is concluded that SDT may help understand the motivational processes of the prevention of unintentional doping in sport. 相似文献
115.
Janet A. Hindler Annie Wong-Beringer Carmen L. Charlton Shelley A. Miller Theodoros Kelesidis Marissa Carvalho George Sakoulas Poochit Nonejuie Joseph Pogliano Victor Nizet Romney Humphries 《Antimicrobial agents and chemotherapy》2015,59(7):4279-4288
Enterococci that are nonsusceptible (NS; MIC > 4 μg/ml) to daptomycin are an emerging clinical concern. The synergistic combination of daptomycin plus beta-lactams has been shown to be effective against vancomycin-resistant Enterococcus (VRE) species in vitro. This study systematically evaluated by in vitro time-kill studies the effect of daptomycin in combination with ampicillin, cefazolin, ceftriaxone, ceftaroline, ertapenem, gentamicin, tigecycline, and rifampin, for a collection of 9 daptomycin-NS enterococci that exhibited a broad range of MICs and different resistance-conferring mutations. We found that ampicillin plus daptomycin yielded the most consistent synergy but did so only for isolates with mutations to the liaFSR system. Daptomycin binding was found to be enhanced by ampicillin in a representative isolate with such mutations but not for an isolate with mutation to the yycFGHIJ system. In contrast, ampicillin enhanced the killing of the LL-37 human antimicrobial peptide against daptomycin-NS E. faecium with either the liaFSR or yycFGHIJ mutation. Antagonism was noted only for rifampin and tigecycline and only for 2 or 3 isolates. These data add support to the growing body of evidence indicating that therapy combining daptomycin and ampicillin may be helpful in eradicating refractory VRE infections. 相似文献
116.
117.
John S. Millar Gissette Reyes-Soffer Patricia Jumes Richard L. Dunbar Emil M. deGoma Amanda L. Baer Wahida Karmally Daniel S. Donovan Hashmi Rafeek Laura Pollan Junichiro Tohyama Amy O. Johnson-Levonas John A. Wagner Stephen Holleran Joseph Obunike Yang Liu Rajasekhar Ramakrishnan Michael E. Lassman David E. Gutstein Henry N. Ginsberg Daniel J. Rader 《The Journal of clinical investigation》2015,125(6):2510-2522
BACKGROUND. Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; therefore, the goal of this study was to determine the kinetic mechanism responsible for the reduction in LDL and ApoB in response to anacetrapib.METHODS. We performed a trial of the effects of anacetrapib on ApoB kinetics. Mildly hypercholesterolemic subjects were randomized to background treatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks. All subjects then added 100 mg anacetrapib to background treatment for 8 weeks. Following each study period, subjects underwent a metabolic study to determine the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and fractional catabolic rate (FCR).RESULTS. Anacetrapib markedly reduced the LDL-ApoB-100 pool size (PS) in both the placebo and ATV groups. These changes in PS resulted from substantial increases in LDL-ApoB-100 FCRs in both groups. Anacetrapib had no effect on LDL-ApoB-100 PRs in either treatment group. Moreover, there were no changes in the PCSK9 PS, FCR, or PR in either group. Anacetrapib treatment was associated with considerable increases in the LDL triglyceride/cholesterol ratio and LDL size by NMR.CONCLUSION. These data indicate that anacetrapib, given alone or in combination with a statin, reduces LDL-ApoB-100 levels by increasing the rate of ApoB-100 fractional clearance.TRIAL REGISTRATION. ClinicalTrials.gov .FUNDING. Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040). NCT00990808相似文献
118.
Whitney E. Melroy Sarah H. Stephens Joseph T. Sakai Helen M. Kamens Matthew B. McQueen Robin P. Corley Michael C. Stallings Christian J. Hopfer Kenneth S. Krauter Sandra A. Brown John K. Hewitt Marissa A. Ehringer 《Behavior genetics》2014,44(4):356-367
Previous studies have shown associations between single nucleotide polymorphisms (SNPs) in gamma aminobutyric acid receptor alpha 2 (GABRA2) and adolescent conduct disorder (CD) and alcohol dependence in adulthood, but not adolescent alcohol dependence. The present study was intended as a replication and extension of this work, focusing on adolescent CD, adolescent alcohol abuse and dependence (AAD), and adult AAD. Family based association tests were run using Hispanics and non-Hispanic European American subjects from two independent longitudinal samples. Although the analysis provided nominal support for an association with rs9291283 and AAD in adulthood and CD in adolescence, the current study failed to replicate previous associations between two well replicated GABRA2 SNPs and CD and alcohol dependence. Overall, these results emphasize the utility of including an independent replication sample in the study design, so that the results from an individual sample can be weighted in the context of its reproducibility. 相似文献
119.
Michael W. Lawlor Marissa G. Viola Hui Meng Rachel V. Edelstein Fujun Liu Ke Yan Elizabeth J. Luna Alexandra Lerch-Gaggl Raymond G. Hoffmann Christopher R. Pierson Anna Buj-Bello Jennifer L. Lachey Scott Pearsall Lin Yang Cecilia J. Hillard Alan H. Beggs 《The American journal of pathology》2014,184(6):1831-1842
X-linked myotubular myopathy is a congenital myopathy caused by deficiency of myotubularin. Patients often present with severe perinatal weakness, requiring mechanical ventilation to prevent death from respiratory failure. We recently reported that an activin receptor type IIB inhibitor produced hypertrophy of type 2b myofibers and modest increases of strength and life span in the severely myopathic Mtm1δ4 mouse model of X-linked myotubular myopathy. We have now performed a similar study in the less severely symptomatic Mtm1 p.R69C mouse in hopes of finding greater treatment efficacy. Activin receptor type IIB inhibitor treatment of Mtm1 p.R69C animals produced behavioral and histological evidence of hypertrophy in gastrocnemius muscles but not in quadriceps or triceps. The ability of the muscles to respond to activin receptor type IIB inhibitor treatment correlated with treatment-induced increases in satellite cell number and several muscle-specific abnormalities of hypertrophic signaling. Treatment-responsive Mtm1 p.R69C gastrocnemius muscles displayed lower levels of phosphorylated ribosomal protein S6 and higher levels of phosphorylated eukaryotic elongation factor 2 kinase than were observed in Mtm1 p.R69C quadriceps muscle or in muscles from wild-type littermates. Hypertrophy in the Mtm1 p.R69C gastrocnemius muscle was associated with increased levels of phosphorylated ribosomal protein S6. Our findings indicate that muscle-, fiber type-, and mutation-specific factors affect the response to hypertrophic therapies that will be important to assess in future therapeutic trials.X-linked myotubular myopathy (XLMTM) is a severe form of congenital myopathy with an estimated incidence of 1:50,000 male births that most often presents with severe perinatal weakness and respiratory failure.1,2 Many patients with XLMTM die within the first year of life despite the use of mechanical ventilation, and no treatments approved by the Food and Drug Administration are available. XLMTM is caused by mutations in the gene that encodes myotubularin (MTM1), which is a phosphoinositide phosphatase thought to be involved in endosomal trafficking, cytoskeletal organization, apoptosis, and/or maintenance of the sarcoplasmic reticulum/T-tubular system within myofibers.3–8 Muscle biopsies from patients with XLMTM display excessively small fibers with increased numbers of fibers that contain central nuclei and central aggregation of organelles.9 Although the number of centrally nucleated fibers bears little relationship to a patient''s prognosis, there is a clear correlation between the degree of fiber smallness at birth and the severity of the patients'' disease.10 Two murine models of myotubularin deficiency are used, the severely symptomatic Mtm1δ4 (also referred to as Mtm1 knockout in prior studies3,11,12) and the moderately symptomatic Mtm1 p.R69C mice,13 both of which display weakness and myofiber smallness and similar pathology to that seen in XLMTM.Because of the relationship between myofiber size and symptomatic severity in patients with XLMTM and in Mtm1δ4 mice, we had previously hypothesized that correction of myofiber smallness in myotubularin deficiency would greatly improve strength. Inhibitors of myostatin or nonfunctional decoys of its receptor, the activin type IIB receptor (ActRIIB), can be used to inhibit this negative regulator of myofiber size, leading to myofiber hypertrophy. Myostatin binds to (and signals through) the ActRIIB to activate the transforming growth factor-β pathway, which prevents progression through the cell cycle and down-regulates several key processes related to myofiber hypertrophy.14,15 We recently reported a trial of ActRIIB-mFC in Mtm1δ4 mice, which produced 17% extension of life span, with transient increases in weight, forelimb grip strength, myofiber size, and myofiber hypertrophy restricted to type 2b myofibers in Mtm1δ4 animals.12 Interestingly, ActRIIB-mFc produces hypertrophy in all muscle fiber types in wild-type (WT) mice,12,16 which suggests that myotubularin deficiency interferes with the activation of hypertrophic pathways in oxidative fibers.We hypothesized that the transience of the therapeutic effects observed in treated Mtm1δ4 mice may have been related to the severity of the disease, so we have now repeated this study in the less severely affected Mtm1 p.R69C mouse.13 Surprisingly, treatment of Mtm1 p.R69C mice did not produce significant increases in animal weight or grip strength, and treatment-induced myofiber hypertrophy was only observed in the Mtm1 p.R69C gastrocnemius muscles. The ability of these muscles to respond to ActRIIB-mFC treatment correlated with treatment-induced increases in satellite cell number and several muscle-specific abnormalities of hypertrophic signaling. The main difference between treatment-responsive (gastrocnemius) and treatment-resistant (quadriceps) muscles in Mtm1 p.R69C mice was related to low levels of phosphorylated ribosomal protein 6 (p-rpS6) and high levels of eukaryotic elongation factor 2 kinase (eEF2K) in the treatment-responsive gastrocnemius muscle that were not observed in other Mtm1 p.R69C muscles or in WT mice. rpS6 and eEF2K are terminal signaling molecules of the insulinlike growth factor-1/Akt and extracellular signal-related kinase (ERK) pathways that are involved in the fine-tuning of global protein synthesis, with a role in the determination of cell size that remains unclear (reviewed in Meyuhas17). Our findings indicate that the response to hypertrophic agents does not always correlate with activities of known hypertrophic pathways, such as the Akt pathway, but unexpectedly varies both by muscle type and fiber type and in XLMTM is affected by the nature of the Mtm1 mutation. These results highlight that there is much we still do not understand about the control of muscle size and emphasize the importance of evaluating multiple muscle and fiber types in future trials of hypertrophic therapies. 相似文献
120.
Jerry H. Gurwitz MD Terry S. Field DSc Jessica Ogarek MS Jennifer Tjia MD MSCE Sarah L. Cutrona MD MPH Leslie R. Harrold MD MPH Shawn J. Gagne BA Peggy Preusse RN Jennifer L. Donovan PharmD Abir O. Kanaan PharmD George Reed PhD Lawrence Garber MD 《Journal of the American Geriatrics Society》2014,62(5):865-871